Movement Disorders

The distinguished investigator at the National Institutes of Health provided insight on the topic of globalizing Parkinson disease genetics, and how it may lead to potential disease-modifying therapies.

The group of experts provided perspectives on the shift in how residency programs are developed and laid out, as well as efforts to increase the number of young neurologists in the field.

Previous neuroimaging studies in Parkinson disease suggest an altered interaction at a structural and functional level between cortical and subcortical areas of the brain that each contribute to gait dysfunction.

Patients treated with the probiotic saw benefits in non-motor symptoms such as sleep, fatigue, and gastrointestinal outcomes.

Falls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

After a year of treatment, patients showed significant improvements in ON time without troublesome dyskinesia, with more apparent effects observed in the high-dose group.

The neurosurgeon at Allegheny Health Network discussed the current uses of GammaTile following tumor removal, and the research needed to unlock greater potential. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Lixisenatide, commonly used to treat type 2 diabetes, has the ability to cross the blood brain barrier and has shown neuroprotective properties in preclinical models of PD.

Significant thinning of GCIPL and INL appeared earlier in individuals with Parkinson disease, being discernible several years prior to clinical presentation.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Cervical dystonia, the most common form of focal dystonia, has shown to be able to be effectively managed with a variety of botulinum toxin formulations.

Neurology News Network for the week ending August 26, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 25, 2023.

Five-year data revealed sustained and significant improvement for patients with tremor as well as an overall improvement in quality of life measures and without any progressive or delayed complications.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Erin Furr-Stimming, MD, FAAN, FANA. [LISTEN TIME: 11 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

A duo of experts from the pivotal, phase 3 ASPEN trial shared commentary on the impact of daxibotulinumtoxinA’s approval for adults with cervical dystonia.

Neurology News Network for the week ending August 19, 2023. [WATCH TIME: 4 minutes]

The approval was based on the phase 3 KINECT-HD study, an 128-patient cohort trial in which valbenazine met its primary end point, demonstrating a statistically significant reduction in UHDRS TMC scores vs placebo.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 18, 2023.

A peer-reviewed analysis revealed critical gaps in care for patients with Parkinson disease in the United States, including disparities affecting women, people of color, and residents of rural areas.

Elevated caregiver depression risk corresponds to increased emergency department usage, hinting at a pivotal link between caregiver well-being and patient healthcare utilization.

Patients on IPX203 received less doses than those on traditional immediate-release carbidopa/levodopa and demonstrated 0.53 more hours of good ON time per day than IR CD/LD.

A new platform showed the ability to effectively detect patients with synucleinopathies using serum samples, improving the time and accuracy for diagnosis of specific neurodegenerative diseases such as Parkinson disease.

The neurosurgeon at Allegheny Health Network provided perspective on how GammaTile therapy is revolutionizing neurosurgery and post-operative processes of brain tumors.

In addition to showing a safe and tolerable safety profile, patients who underwent the procedure showed a 7-point median improvement on the upper extremity Fugl-Meyer Assessment when used in combination with physical rehabilitation.

The phase 2 clinical trial ACTIVATE investigating BIA 28-6156 for Parkinson disease is currently screening for patients in North America and with the Europe-based study beginning sometime during the third quarter of 2023.